Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline and Biocellular Markers in Pediatric Anxiety
NCT02189213Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Jul 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sertraline in generalized anxiety disorder (GAD), separation anxiety disorder (SAD) and Social Anxiety Disorder (SAD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Clinical Global Impression-Improvement at 12 weeks. Started Jul 2014; status: terminated.
02
Drugs
sertraline
03
Conditions
generalized anxiety disorder (GAD)separation anxiety disorder (SAD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT02189213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189213.